Physician profile
Michael E Davis
NPI 1922115229
$3,243.99
in general payments reported to CMS, 2019-2025
28 companies · $388 in 2025
The $388 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $235 · 2022: $462 · 2023: $1,263 · 2024: $896 · 2025: $388.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,547.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,547.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $774.61 | 2021-2025 | Proclaim, Prodigy, Octrode |
| Boston Scientific Corporation | $532.88 | 2022-2025 | Wavewriter Alpha Prime 16 |
| Nalu Medical, INC. | $226.37 | 2021-2024 | Nalu Neurostimulation System |
| Spinal Simplicity, LLC | $194.98 | 2022 | |
| Painteq LLC | $185.30 | 2023 | Painteq |
| Nevro Corp. | $183.24 | 2022-2024 | Senza |
| Vertex Pharmaceuticals Incorporated | $141.79 | 2025 | |
| Collegium Pharmaceutical, INC. | $139.62 | 2023-2024 | Belbuca, Xtampza |
| Saluda Medical Americas, INC. | $112.15 | 2023-2024 | Evoke, Evoke Scs |
| Pfizer INC. | $83.20 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $80.16 | 2021-2025 | Relistor |
| Vertos Medical, INC. | $80.13 | 2021-2024 | Mild Device Kit |
| Impel Pharmaceuticals INC. | $73.37 | 2023 | Trudhesa |
| Si-Bone, INC. | $66.46 | 2022-2024 | |
| Tersera Therapeutics LLC | $56.28 | 2023-2024 | Prialt |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotronik Nro, INC. | $46.18 | 2025 | Prospera |
| Stryker Corporation | $40.41 | 2021 | |
| Depuy Synthes Sales INC. | $40.28 | 2023 | Orthovisc |
| Relievant Medsystems, INC. | $28.86 | 2023 | Intracept |
| Grt US Holding, INC. | $21.58 | 2021 | |
| Avanos Medical | $21.04 | 2023 | Genvisc 850 Sodium Hyaluronate |
| Hikma Pharmaceuticals USA | $21.00 | 2022 | |
| Daiichi Sankyo INC. | $20.18 | 2023 | Injectafer |
| Lundbeck LLC | $18.27 | 2021 | |
| Redhill Biopharma INC. | $15.10 | 2021 | |
| Azurity Pharmaceuticals, INC. | $14.51 | 2023 | Horizant |
| Forte Bio-Pharma LLC | $13.06 | 2023 | Prolate, Nalocet |
| Arbor Pharmaceuticals, INC. | $12.98 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.